Alexion Pharmaceuticals (ALXN) : March Altus Capital Management Lp added new position in Alexion Pharmaceuticals during the Fourth Quarter. The investment management firm now holds 8,599 shares of Alexion Pharmaceuticals which is valued at $1.1 Million according to most recent disclosure to SEC.Alexion Pharmaceuticals makes up approximately 10.40% of March Altus Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Evercore Wealth Management boosted its stake in ALXN during the Q4 period, The investment management firm added 32 additional shares and now holds a total of 1,557 shares of Alexion Pharmaceuticals which is valued at $199,997. Alexion Pharmaceuticals makes up approx 0.01% of Evercore Wealth Management’s portfolio.Loomis Sayles Co L P boosted its stake in ALXN during the Q4 period, The investment management firm added 59,344 additional shares and now holds a total of 548,911 shares of Alexion Pharmaceuticals which is valued at $70.5 Million. Alexion Pharmaceuticals makes up approx 0.20% of Loomis Sayles Co L P’s portfolio.Leuthold Group boosted its stake in ALXN during the Q4 period, The investment management firm added 1,017 additional shares and now holds a total of 23,274 shares of Alexion Pharmaceuticals which is valued at $3 Million. Alexion Pharmaceuticals makes up approx 0.32% of Leuthold Group’s portfolio. Lockheed Martin Investment Management Co sold out all of its stake in ALXN during the fourth quarter. The investment firm sold 6,500 shares of ALXN which is valued $834,925.
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $1.10. The company had revenue of $700.90 million for the quarter, compared to analysts expectations of $702.36 million. The company’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.30 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Downgraded by Robert W. Baird on Mar 8, 2016 to ” Neutral” and Lowered the Price Target to $ 170 from a previous price target of $221 .Citigroup Initiated Alexion Pharmaceuticals on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $165.Shares were Reiterated by UBS on Feb 4, 2016 to “Buy” and Lowered the Price Target to $ 200 from a previous price target of $222 .
Alexion Pharmaceuticals opened for trading at $135.88 and hit $138.0699 on the upside on Wednesday, eventually ending the session at $134.82, with a gain of 0.21% or 0.28 points. The heightened volatility saw the trading volume jump to 12,63,283 shares. Company has a market cap of $30,374 M.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.